M
Myron S. Cohen
Researcher at University of North Carolina at Chapel Hill
Publications - 576
Citations - 50913
Myron S. Cohen is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Population & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 103, co-authored 549 publications receiving 46021 citations. Previous affiliations of Myron S. Cohen include University of Massachusetts Medical School & Scripps Health.
Papers
More filters
Journal ArticleDOI
Does ART prevent HIV transmission among MSM
Kathryn E. Muessig,M. Kumi Smith,Kimberly A. Powers,Ying Ru Lo,David N. Burns,Andrew E. Grulich,Andrew E. Grulich,Andrew N. Phillips,Myron S. Cohen +8 more
TL;DR: The benefits of treatment as prevention for MSM are highly plausible, but not certain, and treatment guidelines for earlier ART initiation should be considered within a combination prevention strategy that includes earlier diagnosis, expanded STI treatment, and structural and behavioral interventions.
Journal ArticleDOI
Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models.
TL;DR: Controlled human infection models have been proposed as a strategy for accelerating SARS-CoV-2 vaccine development, but scientific and technical fact...
Journal ArticleDOI
Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry.
Arlene S. Pereira,Kathryn B Kenney,Myron S. Cohen,James Edwin Hall,Joseph J. Eron,Richard R. Tidwell,John A. Dunn +6 more
TL;DR: This validated HPLC-MS-MS method was developed and validated and used to analyze seminal samples obtained from six HIV-positive patients prescribed lamivudine and zidovudine.
Journal ArticleDOI
Preexposure prophylaxis for HIV--where do we go from here?
Myron S. Cohen,Lindsey R. Baden +1 more
TL;DR: The rate of HIV acquisition in young, healthy adults (mostly women) was 3 to 5 per 100 person-years in two trials studying heterosexual transmission of HIV in sub-Saharan Africa, now reported in the Journal.
Journal ArticleDOI
Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial.
Susan H. Eshleman,Sarah E. Hudelson,Andrew D. Redd,Ronald Swanstrom,San San Ou,Xinyi Cindy Zhang,Li Hua Ping,Estelle Piwowar-Manning,Stephen F. Porcella,Matthew Sievers,Craig Martens,Daniel Bruno,Elena Dukhovlinova,Marybeth McCauley,Theresa Gamble,Jessica M. Fogel,Devin Sabin,Thomas C. Quinn,Thomas C. Quinn,Laurence Gunde,Madalitso Maliwichi,Nehemiah Nhando,Victor Akelo,Sikhulile Moyo,Ravindre Panchia,Nagalingeswaran Kumarasamy,Nuntisa Chotirosniramit,Marineide Gonçalves de Melo,José Henrique Pilotto,Beatriz Grinsztejn,Kenneth H. Mayer,Kenneth H. Mayer,Ying Q. Chen,James P. Hughes,Myron S. Cohen +34 more
TL;DR: It was demonstrated that antiretroviral therapy (ART) prevents HIV transmission in serodiscordant couples and was the likely source of the partner's infection.